PETITION TO THE LOUISIANA HOUSE OF REPRESENTATIVES

RE: URGENT OPPOSITION TO SENATE BILL 154 (SB 154) AND STRONG SUPPORT FOR HOUSE BILL 253 (HB 253) – PROTECTING CONSUMER CHOICE AND PUBLIC HEALTH THROUGH RESPONSIBLE REGULATION OF KRATOM

To the Honorable Members of the Louisiana House of Representatives,

We, the undersigned citizens and residents of Louisiana, and other concerned supporters across the United States, respectfully and urgently implore you to VOTE NO on Senate Bill 154 (SB 154) and to SUPPORT and advance House Bill 253 (HB 253), the "Kratom Consumer Protection Act." This critical moment demands a balanced, informed approach to kratom policy that prioritizes public health and consumer safety over misguided prohibition.

SB 154, which seeks to classify the active components of kratom as Schedule I controlled substances, represents an extreme, disproportionate, and potentially harmful public policy. A blanket prohibition would not only disregard the experiences of countless responsible adult users but also undermine public health by driving a currently accessible substance into a dangerous, unregulated black market. Instead of enacting a ban, we advocate for a responsible regulatory framework, as outlined in HB 253, that prioritizes consumer safety, informed choice, and accurate information.

It is estimated that millions of Americans responsibly use kratom for their well-being. It is estimated that over 300,000 in Louisiana consume this plant alone. A ban would strip these individuals of a crucial aid and could push them towards more dangerous, unregulated substances.

Our opposition to SB 154 and strong support for HB 253 are rooted in the following critical considerations:

Arguments for Opposing SB 154 (Kratom Ban)

 * Public Health and Safety Risk: Banning kratom will not eliminate its use but will drive its market underground, creating a dangerous black market with no quality control, testing, or labeling. In such an unregulated environment:

   * Consumers would be at higher risk of purchasing adulterated products (e.g., laced with other dangerous substances, like fentanyl) or products with harmful contaminants (e.g., heavy metals, bacteria like Salmonella), which have been identified as a concern by the FDA in unregulated products, leading to serious illness and even deaths.

   * There would be no accurate information on potency or ingredients, increasing the risk of adverse reactions due to unknown concentrations or unlisted substances.

     A ban is a counterproductive public health measure that will exacerbate, not alleviate, safety concerns by removing all oversight and consumer protections.

 * Mischaracterization of Kratom's Mechanism and Safety Profile: While kratom's primary active alkaloids, mitragynine and 7-hydroxymitragynine, interact with opioid receptors, their mechanism of action is significantly different from classic opioid drugs. Scientific studies indicate that these compounds act as partial agonists at mu-opioid receptors. This distinct pharmacological profile, sometimes referred to as "biased agonism," is crucial because it suggests they may not contribute to the significant respiratory depression that is the primary cause of death in opioid overdoses. Classifying kratom as a Schedule I substance, akin to heroin or LSD, ignores this unique pharmacology and its potential for a different, potentially safer, profile regarding respiratory depression.

 * Impact on Pain Management and Well-being: Many individuals rely on kratom for chronic pain relief and to manage symptoms of opioid withdrawal, acting as a vital natural supplement. Criminalizing kratom would not only strip these individuals of a crucial aid but could also push them towards more dangerous, unregulated illicit opioids or highly addictive prescription drugs, exacerbating the existing opioid crisis.

 * Overstated Adverse Effects & Conflation with Polysubstance Use: Reports of adverse effects from kratom do exist, but the prevalence of severe adverse events and deaths specifically attributable to kratom alone is often overstated or conflated with polysubstance use. Data from U.S. Poison Control Centers (PCCs), while showing an increase in kratom-related calls, also highlight that serious adverse effects when kratom is used alone are rare. For instance, from January 2011 through December 2017, nearly all reported deaths involving kratom also included the co-ingestion of other drugs or substances, making it difficult to definitively attribute causality solely to kratom. A ban based on anecdotal or polysubstance-related adverse events unfairly penalizes all users and overlooks the far greater public health crisis associated with illicit fentanyl and other highly potent controlled substances.

 * Personal Liberty and Over-criminalization: Responsible adults should have the right to choose natural alternatives for their well-being, especially when those alternatives can improve their quality of life and reduce reliance on pharmaceuticals. Classifying kratom alongside dangerous Schedule I drugs like heroin and LSD is disproportionate and would unnecessarily burden our criminal justice system, creating new felons out of otherwise law-abiding citizens.

Arguments for Supporting HB 253 (Kratom Consumer Protection Act)

 * Comprehensive Consumer Safety: HB 253 establishes critical safeguards that directly address legitimate safety concerns without resorting to a ban. These include:

   * Mandatory third-party lab testing for contaminants like heavy metals, bacteria (e.g., Salmonella), and adulterants (e.g., other dangerous substances).

   * Strict labeling requirements, including accurate alkaloid content (mitragynine and 7-hydroxymitragynine) and clear warnings.

   * Prohibitions on sales to minors (under 21).

   * Limits on 7-hydroxymitragynine content to ensure a safer product.

     These regulations provide consumers with transparent information, allowing for informed choices and mitigating genuine risks.

 * Responsible and Regulated Market: By regulating the market, HB 253 allows for the continued availability of kratom while protecting consumers from unregulated and potentially dangerous products. This is a pragmatic approach that acknowledges public demand while prioritizing safety. A regulated market is far more effective at combating the sale of dangerous, unregulated products than an outright ban, which only fuels the black market.

Conclusion: Prioritizing Public Health Through Informed Policy

SB 154's proposed outright ban on kratom is an overly broad and potentially harmful policy. It mischaracterizes kratom's safety profile by conflating it with more dangerous substances and overlooks the evidence suggesting its potential for safe use under controlled conditions. Instead of pushing kratom into the shadows, Louisiana should consider a regulatory framework that prioritizes consumer safety through rigorous testing, clear labeling, and age restrictions. This approach would allow adults to make informed choices while mitigating genuine risks, representing a more balanced and effective public health strategy than a complete prohibition.

Therefore, we respectfully implore the members of the Louisiana House of Representatives to VOTE NO on SB 154 and instead champion HB 253 as the responsible path forward for Louisiana. Please vote with science, public health, and individual liberty in mind.

Sincerely,

The Undersigned Citizens and Residents of Louisiana, and other concerned Supporters across the United States